Company intelligence / Profile preview

Novaremed

Basel, Basel-Stadt, Switzerlandnovaremed.com ↗

Ownership: Private
Development stage: Other

Overview

The company’s lead candidate, NRD.E1, an orally active non-opioid small molecule with a novel mechanism of action, is currently in an NIH-sponsored Phase 2b clinical trial for painful diabetic peripheral neuropathy. MP‑101 has completed Phase 2 studies for prevention of chemotherapy-induced peripheral neuropathy. MP‑103 remains at the preclinical stage targeting CIPN and other forms of peripheral neuropathy. No pivotal or registration-enabling data have been reported as of June 2025.

Therapeutic areas: Neurology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

4 assets

nispomeben

3 more assets in the full pipeline.

Request access →

Partnerships

Interested in pharmaceutical partnerships (none specified)

Beyond the preview

Go deeper on Novaremed.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Novaremed.

Explore the full profile